Contemporary National Patterns of Eligibility and Use of Novel Lipid‐Lowering Therapies in the United States

BACKGROUND: The emergence of PCSK9i (proprotein convertase subtilisin kexin type 9 inhibitor) and icosapent ethyl (IPE) has expanded the role of lipid‐lowering therapies beyond statins. Despite recommendations by clinical practice guidelines, their national eligibility and use rates remain unclear....

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Miles, Aghajani Nargesi, Arash, Nasir, Khurram, Bhatt, Deepak L., Khera, Rohan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9683659/
https://www.ncbi.nlm.nih.gov/pubmed/36102276
http://dx.doi.org/10.1161/JAHA.122.026075

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9683659/
https://www.ncbi.nlm.nih.gov/pubmed/36102276
http://dx.doi.org/10.1161/JAHA.122.026075

Ejemplares similares